Why Publish with Kidney Cancer(2)KCA 5:4, review #1, fig 1KCA 4:3, article 3, fig 2KCA 4:2, article 6, fig 1KCA 3:2, article 5, figure2KCA 3:1, article 2, figure 1KCA 3:1, article 1, figure 1Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (2:1)Perioperative Systemic Therapy for Metastatic Renal Cell CarcinomaRationale to prime the immune systemNew KCA issue

Your kidney cancer research in basic science, translational medicine and clinical medicine is important. And you have a choice when you select a journal in which to publish your results. We invite you to submit your manuscript to Kidney Cancer, now Gold Open Access!

Review article that looks at the present and future of treatment paradigms for sarcomatoid renal cell carcinoma. From: Candelario, et al., Kidney Cancer, Vol.5, Iss.5, pp. 167-179, 2021

Review article that looks to validate the association of rs307826 in VEGFR3 to first-line sunitinib outcome in an independent cohort of m-ccRCC patients. From: Beuselinck, et al., Kidney Cancer, Vol.4, Iss.3, pp. 139-149, 2020

Renal cell carcinoma with inferior vena cava extension. A modified thrombus classification was proposed with visuals of successive levels defined, in part, as shown in the visual. From: Leibovich, et al., Kidney Cancer, Vol.4, Iss.2, pp. 111-115, 2020

This research article examines the role microRNAs (miRNAS) in the progression of cancer types, including clear cell renal cell carcinoma (ccRCC). L: Prognostic miRNAs (pink) and master regulator (blue) of the prognostic genes. R: Identified 96 miR-22 target genes. From: Gong, et al., KCA 3:2, pp. 119-132, 2019

This review examines cell-free circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma. Visual illustrates circulating cell-free DNA (cfDNA) and ctDNA found in serum and plasma fractions from blood. From: Hahn, et al., Kidney Cancer, Vol.3, Iss.1, pp. 7-13, 2019

This review examines radiation therapy in the treatment of renal cell carcinoma with an aim to expand the discussion on treatment options. Visual is an example of a patient treated with stereotactic ablative radiotherapy for a renal tumor. From: Choi and Yu, Kidney Cancer, Vol.3, Iss.1, pp. 1-6, 2019

This study indicates that 4LT appears to have activity in mRCC patients. The figure shows total number of patients receiving the therapies (A); with (B) indicating therapies given to patients who received 4LT. From: Stukalin, et al., Kidney Cancer, Vol.2, Iss.1, pp. 31–36, 2018.

Renal cell carcinoma's disease biology: inactivated VHL gene leads to overexpression of HIF. Genes activated by HIF transcript growth factors such as VEGF, PDGF and FGF. From: Maia et al., Kidney Cancer, Vol.1, Iss.1, pp. 15-29, 2017

Rationale to prime the immune system with PD-1 blockade prior to nephrectomy. From: Harshman et al., Kidney Cancer, Vol.1, Iss.1, pp. 31-40, 2017

Since its launch in 2017, Kidney Cancer has been going from strength to strength. Check out the very latest articles in the journal by clicking on the banner image to go straight to the content!

Welcome to Kidney Cancer

Editorial Board

Primo Nery Lara

Primo N. Lara Jr, MD

University of California Davis Comprehensive Cancer Center
Sacramento, CA, USA

Email: kca@iospress.com

Peter Mulder

Peter Mulders, MD, PhD

Radboud UMC Nijmegen,The Netherlands

Email: kca@iospress.com


Submission Guidelines




Authors are requested to submit their manuscript electronically to the online submission system msTracker. Note that the manuscript should be uploaded as one file with tables and figures included.


No front page content has been created yet.